Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)Eric F. Morand, Thomas Dörner, Edward M Vital et al.|The Lancet|2023Cited by 151